The stock of Vital Therapies Inc (NASDAQ:VTL) hit a new 52-week low and has $4.58 target or 12.00% below today’s $5.20 share price. The 6 months bearish chart indicates high risk for the $164.01M company. The 1-year low was reported on Nov, 3 by Barchart.com. If the $4.58 price target is reached, the company will be worth $19.68M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 14,166 shares traded hands. Vital Therapies Inc (NASDAQ:VTL) has declined 44.27% since April 1, 2016 and is downtrending. It has underperformed by 45.48% the S&P500.
Vital Therapies Inc (NASDAQ:VTL) Ratings Coverage
Out of 6 analysts covering Vital Therapies Inc (NASDAQ:VTL), 2 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 33% are positive. Vital Therapies Inc has been the topic of 10 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The rating was downgraded by BTIG Research to “Neutral” on Monday, October 26. The firm has “Neutral” rating given on Tuesday, September 29 by SunTrust. Canaccord Genuity maintained Vital Therapies Inc (NASDAQ:VTL) on Monday, August 24 with “Buy” rating. The firm has “Outperform” rating given on Monday, August 10 by Credit Suisse. The company was initiated on Friday, August 7 by BTIG Research. The firm has “Buy” rating given on Monday, August 24 by SunTrust. The rating was downgraded by William Blair on Monday, August 24 to “Outperform”. The rating was downgraded by Suntrust Robinson on Tuesday, September 29 to “Neutral”. The rating was downgraded by Credit Suisse to “Neutral” on Monday, August 24. The rating was downgraded by Suntrust Robinson on Monday, August 24 to “Neutral”.
According to Zacks Investment Research, “Vital Therapies, Inc. is a biotherapeutic company. It is focused on developing a cell-based therapy targeting the treatment of acute liver failure. The Company operates in the United States, Europe, and China. Vital Therapies, Inc. is based in San Diego, California.”
Insitutional Activity: The institutional sentiment increased to 1.58 in Q2 2016. Its up 0.13, from 1.45 in 2016Q1. The ratio improved, as 8 funds sold all Vital Therapies Inc shares owned while 11 reduced positions. 7 funds bought stakes while 23 increased positions. They now own 8.18 million shares or 10.33% less from 9.13 million shares in 2016Q1.
Citigroup has invested 0% of its portfolio in Vital Therapies Inc (NASDAQ:VTL). Price T Rowe Assocs Md accumulated 0% or 17,900 shares. The New Jersey-based Kcg has invested 0% in Vital Therapies Inc (NASDAQ:VTL). Walleye Trading Ltd Llc holds 449 shares or 0% of its portfolio. Ironwood Financial Limited Liability holds 0% or 860 shares in its portfolio. The California-based Schwab Charles Invest Mgmt has invested 0% in Vital Therapies Inc (NASDAQ:VTL). The New York-based New York State Common Retirement Fund has invested 0% in Vital Therapies Inc (NASDAQ:VTL). Fmr Limited Company, a Massachusetts-based fund reported 2.02M shares. Moreover, Jpmorgan Chase Comm has 0% invested in Vital Therapies Inc (NASDAQ:VTL) for 940 shares. Parametric Assoc Lc has invested 0% of its portfolio in Vital Therapies Inc (NASDAQ:VTL). D E Shaw And Incorporated holds 0% of its portfolio in Vital Therapies Inc (NASDAQ:VTL) for 46,667 shares. Nationwide Fund accumulated 14,423 shares or 0% of the stock. Amer Int Inc holds 0% of its portfolio in Vital Therapies Inc (NASDAQ:VTL) for 13,632 shares. Credit Suisse Ag last reported 27,814 shares in the company. Bank Of America De last reported 8,648 shares in the company.
Insider Transactions: Since August 11, 2016, the stock had 1 insider buy, and 0 sales for $699,999 net activity. Hasnain Faheem had bought 118,243 shares worth $699,999 on Thursday, August 11.
More recent Vital Therapies Inc (NASDAQ:VTL) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on April 16, 2014. Also Quotes.Wsj.com published the news titled: “News Vital Therapies Inc.VTL” on November 24, 2013. Globenewswire.com‘s news article titled: “Vital Therapies Receives FDA Guidance; Announces Upcoming Launch of VTL-308 …” with publication date: November 19, 2015 was also an interesting one.
VTL Company Profile
Vital Therapies, Inc., incorporated on January 13, 2004, is a biotherapeutic company. The Firm is focused on developing a human hepatic cell treatment targeting acute forms of liver failure. The Company’s product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant. The ELAD System is a liver support system containing immortal human liver-derived cells, or VTL C3A cells. The Firm initiated a Phase III clinical trial in severe acute alcoholic hepatitis (sAAH), referred to as VTL-308. VTL-308 is a randomized, open-label, multicenter, controlled, pivotal study, designed to evaluate the ELAD System in subjects with sAAH. It is based on pre-specified and post-hoc analyses of its VTI-208 phase III clinical trial in alcohol-induced liver decompensation (AILD). The Company’s ELAD System consists of approximately four disposable ELAD C3A cell cartridges containing its human liver-derived C3A cells attached to a reusable delivery device using customized disposable tubing sets. The delivery device is based on a cardio-pulmonary bypass machine, which it has configured for the ELAD System treatment. This unit and customized disposable sets are attached to the ELAD C3A cell cartridges where the patient’s blood plasma is treated by its VTL C3A cells before being returned to the patient. Treatment will generally consist of a single session of continuous allogeneic cellular therapy.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.